Patents Examined by Maria Marvich
  • Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
    Patent number: 10328136
    Abstract: In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: June 25, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen
  • Oncolytic adenoviruses for treating cancer
    Patent number: 10316065
    Abstract: The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously results in tumour volume regressions. Therefore, the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: June 11, 2019
    Assignees: Fundacio Institut d Investigacio Biomedica de Bellvitge (IDIBELL), Institut Catala D Oncologia
    Inventors: Sònia Guedan Carrió, Manel Maria Cascallo Piqueras, Ramon Alemany Bonastre
  • Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis
    Patent number: 10301647
    Abstract: The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoathritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (Il-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (Il-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (Il-1Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: May 28, 2019
    Assignee: Baylor College of Medicine
    Inventors: Brendan Lee, Kilian Guse, Zhechao Ruan
  • Use of adenoviruses and nucleic acids that code for said viruses
    Patent number: 10300096
    Abstract: The present invention is related to the use of a virus, preferably an adenovirus, for the manufacture of a medicament, whereby the virus is replication deficient in cells which do not have YB-1 in the nucleus, and the virus codes for an oncogene or oncogene product, in particular an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, whereby the gene is selected from the group comprising E1B55kDa, E4orf6, E4orf3 and E3ADP.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: May 28, 2019
    Inventor: Per Sonne Holm
  • Recombinant virus products and methods for inhibition of expression of DUX4
    Patent number: 10301649
    Abstract: The present invention relates to RNA interference-based methods for inhibiting the expression of the DUX4 gene, a double homeobox gene on human chromosome 4q35. Recombinant adeno-associated viruses of the invention deliver DNAs encoding microRNAs that knock down the expression of DUX4. The methods have application in the treatment of muscular dystrophies such as facioscapulohumeral muscular dystrophy.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: May 28, 2019
    Assignee: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Scott Quenton Harper, Jian Liu, Sara Coppens, Lindsay Wallace
  • Paratransgenic system for the biocontrol of disease-transmitting mosquitos
    Patent number: 10294475
    Abstract: The inventive technology relates to novel paratransgenic strategies for the control of pathogens. The inventive technology may specifically include a novel paratransgenic system configured to deliver one or more inhibitory RNA molecules to pathogen/disease-transmitting organisms. In a preferred embodiment, the invention may include one or more genetically engineered enteric bacteria configured to deliver one or more interfering RNA molecules to pathogen/disease-transmitting mosquitos.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: May 21, 2019
    Assignee: PEBBLE LABS, INC.
    Inventors: Richard Sayre, Jiaannong Xu
  • Compositions and methods for promoting the mineralization of biological tissue
    Patent number: 10293031
    Abstract: This invention relates to compositions and methods for activating and promoting mineralization in tissue that does not normally mineralize, specifically intervertebral discs. The composition comprises agents that increase the expression of the gene that encodes TNAP and/or the activation, amount or activity of TNAP protein, and agents that decrease the expression of ANK and/or ENPP and/or the activation, amount or activity of these proteins. The composition can be in the form of a cell or cells. The invention also relates to methods of using the composition.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: May 21, 2019
    Assignee: NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY
    Inventors: Matthew E. Cunningham, Agata Krzyzanowska
  • Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
    Patent number: 10265417
    Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: April 23, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Guangping Gao, Mauricio R. Alvira, Luc H. Vandenberghe
  • Attenuated reovirus
    Patent number: 10260049
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid ?1 protein and expresses a mutated reoviral outer capsid ?3 protein.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: April 16, 2019
    Assignee: VIROCURE, INC.
    Inventors: Manbok Kim, Randal N. Johnston
  • Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
    Patent number: 10258698
    Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 16, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Stephen G. Hoge, Örn Almarsson, David D. Hile, Ciarán Lawlor, John Podobinski, Staci Sabnis, Antonin de Fougerolles, Divakar Ramakrishnan, Kristy M. Wood
  • CLDN5 mini-promoters
    Patent number: 10253330
    Abstract: Isolated polynucleotides comprising a CLDN5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The mini-promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: April 9, 2019
    Assignee: The University of British Columbia
    Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Daniel Goldowitz, Charles de Leeuw
  • Devices, systems and methods for optogenetic modulation of action potentials in target cells
    Patent number: 10220092
    Abstract: Aspects of the disclosure include devices, systems and methods for optogenetic modulation of action potentials in target cells. The subject devices include light-generating devices, control devices, and delivery devices for delivering vectors to target cells. The subject systems include light-activated proteins, response proteins, nucleic acids comprising nucleotide sequences encoding these proteins, as well as expression systems that facilitate expression of these proteins in target cells. Also provided are methods of using the subject devices and systems to optogenetically inhibit and intercept action potentials in target cells, e.g., to treat a neurological or psychiatric condition in a human or non-human animal subject.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: March 5, 2019
    Assignees: The Board of Trustees of The Leland Stanford Junior University, HUMBOLDT-UNIVERSITAT ZU BERLIN
    Inventors: Karl A. Deisseroth, Emily Anne Ferenczi, Peter Hegemann
  • Production of viral vectors
    Patent number: 10167485
    Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: January 1, 2019
    Assignee: The Regents of the University of Michigan
    Inventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
  • Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
    Patent number: 10159753
    Abstract: The present invention relates to vectors containing liver-specific regulatory sequences and codon-optimized factor IX or factor VIII genes, methods employing these vectors and uses of these vectors. Expression cassettes and vectors containing these liver-specific regulatory elements and codon-optimized factor IX or factor VIII genes are also disclosed. The present invention is particularly useful for applications using gene therapy, in particular for the treatment of hemophilia A and B.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: December 25, 2018
    Assignee: Vrije Universiteit Brussel
    Inventors: Thierry Vandendriessche, Marinee Chuah
  • Subfamily E simian adenoviruses A1321, A1325, A1295, A1309, A1316 and A1322 and uses thereof
    Patent number: 10149873
    Abstract: Recombinant vectors comprise simian adenovirus A1321 (SAdV-A1321), SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1321, SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: December 11, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Soumitra Roy, James M. Wilson
  • Methods of modifying a target nucleic acid with an Argonaute
    Patent number: 10125375
    Abstract: This disclosure provides for compositions and methods for the use of designed nucleic acid-targeting nucleic acids, Argonautes, and complexes thereof.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: November 13, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: John Van Der Oost, Daniël Christianus Swarts, Andrew Paul May, Rachel E. Haurwitz
  • Method for cell culture
    Patent number: 10125349
    Abstract: A method for stem or progenitor cell culture. More precisely, the invention relates to a method for cell culture using one or more I?I (inter-alpha trypsin inhibitor or Inter-alpha inhibitor) protein(s) or part(s) thereof as a component in a cell culture media or a coating on a cell culture surface material. Furthermore the invention relates to a cell culture media and a cell culture coating/matrix provided with one or more I?I proteins(s) or part(s) thereof.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: November 13, 2018
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Sara Pijuan Galito, Christoffer Tamm, Cecilia Anneren
  • Reagent for gene-drug therapeutics
    Patent number: 10100331
    Abstract: The present invention relates to a composition for transfecting a cell with a genetic material comprising a first agent capable of directing the genetic material away from the acidic compartments in the cell and a second agent capable of stabilizing the microtubule or a network thereof. The invention also relates to the use of the composition in the manufacture of a medicament for treating a disease, a method for delivering a genetic material into a cell and a kit.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: October 16, 2018
    Assignee: Agency for Science, Technology and Research
    Inventors: Heng-Phon Too, Yoon Khei Ho, Lihan Zhou
  • Recombinant adenovirus with increased safety and anticancer activities, and use thereof
    Patent number: 10077430
    Abstract: The present invention relates to a recombinant adenovirus with increased in-vivo safety, tissue specificity, and anticancer activities, and a use thereof. Specifically, the recombinant adenovirus comprising: a promoter of the liver tissue-specific phosphoenolpyruvate carboxykinase (PEPCK) gene; a trans-splicing ribozyme which is operably linked to the promoter and acts on a cancer-specific gene; a therapeutic gene or a reporter gene which is linked to the 3? exon of the ribozyme; and a serotype 35 fiber knob and a serotype 5 shaft, in which the orf4 gene is deleted from adenovirus E1, E3 and E4 orf1, shows remarkable in-vivo safety, high specificity for a target tissue, and remarkable anticancer effects, and thus can be useful for an anticancer drug or a cancer diagnostic agent as a gene delivery vector.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: September 18, 2018
    Assignee: NATIONAL CANCER CENTER
    Inventors: Sang Jin Lee, Yun-Hee Kim, In-Hoo Kim, Seong-Wook Lee, Jin-Sook Jeong, Sang Young Han
  • Method of modulating cell resistance
    Patent number: 10066233
    Abstract: The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: September 4, 2018
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Rodolphe Barrangou, Patrick Boyaval, Christophe Fremaux, Philippe Horvath, Dennis Romero